Value of cognitive fusion targeted and standard systematic transrectal prostate biopsy for prostate cancer diagnosis

The aim of this study was to compare the accuracies of cognitive fusion-guided targeted biopsy(TB),systematic biopsy(SB),and combined TB+SB for the detection of prostate cancer(PCa)and clinically significant PCa(csPCa)in males with lesions detected by magnetic resonance imaging(MRI).We conducted a retrospective analysis of individuals who underwent prostate biopsy at Peking University People's Hospital(Beijing,China),with an emphasis on patients with both transrectal TB and SB.The main objective was to determine the precisions of SB,TB,and TB+SB for diagnosing PCa and csPCa.We also evaluated the detection rates of TB,SB,TB+ipsilateral-SB(ipsi-SB),TB+contralateral-SB(contra-SB),and TB+SB for PCa and csPCa in patients with unilateral MRI lesions.We compared the diagnostic yields of the various biopsy schemes using the McNemar’s test.A total of 180 patients were enrolled.The rates of PCa detection using TB,SB,and TB+SB were 52.8%,62.2%,and 66.7%,respectively,and the corresponding rates for csPCa were 46.1%,56.7%,and 58.3%,respectively.Among patients with unilateral MRI lesions,the PCa detection rates for TB,SB,TB+ipsi-SB,TB+contra-SB,and TB+SB were 53.3%,64.8%,65.6%,61.5%,and 68.0%,respectively.TB+ipsi-SB detected 96.4%of PCa and 95.9%of csPCa cases.These findings suggest that the combination of TB+SB has better diagnostic accuracy compared with SB or TB alone.For patients with unilateral MRI lesions,the combination of TB+ipsi-SB may be suitable in clinical settings.

Multivariate analysis of factors predicting surgical intervention for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation

Hemorrhagic cystitis(HC),which is characterized by a congested vasculature and extensive hemorrhage in the bladder lamina propria,is often secondary to chemotherapy,external radiation therapy,allogeneic hematopoietic stem cell transplantation(Allo-HSCT),and/or opportunistic infection.[1]The incidence of HC after Allo-HSCT has been reported to range between 1.3%and 20%.[2]The severity of HC may vary from bladder irritation symptoms with mild hematuria,which is observed in most cases and is resolved with conservative management,such as adequate hydration and bladder irrigation,to transfusion-dependent hemorrhage and/or a lower urinary tract obstruction post renal failure.Other strategies,including bladder irrigation with intravesical alum,formalin,aminocaproic acid,or prostaglandin and hyperbaric oxygen therapy,have been reported,with the resolution of bleeding in the majority of cases.[3]However,for patients in whom these measures fail and the lower urinary tract becomes obstructed by numerous blood clots,further surgery,including internal iliac angioembolization,cystoscopy with control of bladder hemorrhage and cystectomy,should be considered.[4]

Development and Initial Validation of the Novel Scale for Assessing Quality of Life of Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Background：There has been no a specific scale to measure quality of life （QOL） for prostate cancer patients receiving androgen deprivation therapy （ADT） to date.This study aimed to develop and initially validate the scale to evaluate QOL for prostate cancer patients receiving ADT.Methods：The scale was developed following international recommendations.Moreover,the items were all generated through literature review and referenced questionnaires.After being reviewed by expert panelists,the revised scale was formed and then completed by a convenience sample of 200 prostate cancer patients from our hospital.Explore factor analysis （EFA） was applied to test the construct validity,then split-half reliability,Cronbach＆#39;s alpha,and test-retest reliability were applied to assess the reliability and stability of the scale.Results：The revised scale contained 22 items and a total of 200 participants had completed the scale.One hundred participants were randomly selected from the total 200 participants to perform EFA with varimax rotation on the revised scale,and ＆quot;hot flashes＆quot; item was deleted for low factor loading.We selected only 3 items from each factor,then,the final scale was formed with 18-items.We selected another 100 participants to perform the EFA again on the final scale.It was demonstrated that the structure with 6 factors explained 72.5% of total variance and factor loading value was above 0.40 in all items of the factors.Moreover,the split-half reliability coefficient,Cronbach＆#39;s alpha,and test-retest reliability coefficient were calculated to be 0.74,0.63,and 0.89,respectively,exhibiting good reliability on the whole.Conclusions：The scale was identified to be a valid and reliable instrument to measure QOL for prostate cancer patients receiving ADT.Moreover,further research is needed to overcome the potential drawbacks.